CRMD Stock Analysis: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$8.27
-0.05 (-0.60%)
▼
5d:
-6.76%
30d:
-7.7%
90d:
+12.98%
HOLD
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Smart Money Accumulation
None View Scanner →
Strength: 6.0/10
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called CRMD this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CRMD trades at premium valuation expecting 66.5% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: CRMD trades at premium valuation expecting 66.5% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $8.27, which is considered slightly low relative to its 30-day fair value range of $8.13 to $8.83. From a valuation perspective, the stock is trading at a premium (Forward PE: 94.0) compared to its historical average (20.3). At these levels, the market is pricing in 66.5% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CRMD is in a strong uptrend. Immediate support is located at $7.58, while resistance sits at $8.98.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+81.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CRMD is in a strong uptrend. Immediate support is located at $7.58, while resistance sits at $8.98.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+81.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$8.13 -
$8.83
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding CRMD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 81.4% below Wall St target ($15.00)
- BEARISH: Market expects 66.5% growth - appears too optimistic based on history
- CAUTION: Recommendation downgraded due to -6.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$8.13 -
$8.83
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$7.58
Resistance Level
$8.98
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
93.98
Wall Street Target
$15.00
(+81.4%)
Revenue Growth (YoY)
226.1%
Earnings Growth (YoY)
42.8%
Profit Margin
45.2%
Valuation Premium vs History
+66.5% premium
PE vs Historical
94.0 vs 20.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+66.5%
(market-implied from PE analysis)
1-Year Target
$12.41
(+50%)
2-Year Target
$18.61
(+125%)
3-Year Target
$27.91
(+238%)
3-Yr Target (if PE normalizes)
(PE: 94→20)
PE COMPRESSION
$6.03
(-27%)
Significant PE compression expected
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 94.0, Growth: -82.5%)
$6.03
(+-27%)
Base:
(SPY PE: 21.8, Growth: -82.5%)
$1.40
(-83%)
Bear:
(PE: 18.5, Growth: -82.5%)
$1.19
(-86%)
📈
Valuation based on Current Earnings
Trailing PE: 3.87 | Current EPS (TTM): $2.17
Bull Case
$4.62
(-44%)
Analyst growth -50.0%, PE expands to 4.3
Base Case
$4.20
(-49%)
Market implied -50.0%, PE stable at 3.9
Bear Case
$5.71
(-31%)
Severe decline -20.0%, PE contracts to 3.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 6:01 PM ET
Data refreshes hourly during market hours. Next update: 7:01 PM
Data refreshes hourly during market hours. Next update: 7:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 52 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$277 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
